Table 3.
TMEM16A, FADD, and PPFIA1 expressions in invasive ductal carcinoma in relation to clinicopathological parameters (n = number of cases)
| |
TMEM16A |
FADD |
PPFIA1 |
Hazard score
c
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| + | - | P | + | - | P | + | - | P | < 2 | ≥ 2 | P | |
| T stage |
|
|
0.284 |
|
|
0.046d |
|
|
0.444 |
|
|
0.069 |
| 1 |
22 |
1 |
|
19 |
4 |
|
22 |
1 |
|
20 |
3 |
|
| 2 to 3 |
64 |
11 |
|
43 |
32 |
|
66 |
9 |
|
50 |
25 |
|
| N stage |
|
|
0.756 |
|
|
0.277 |
|
|
1 |
|
|
0.316 |
| 0 |
37 |
4 |
|
29 |
12 |
|
37 |
4 |
|
32 |
9 |
|
| 1 to 3 |
49 |
8 |
|
33 |
24 |
|
51 |
6 |
|
38 |
19 |
|
| Grade |
|
|
0.756 |
|
|
0.285 |
|
|
1 |
|
|
0.197 |
| 1 to 2 |
48 |
8 |
|
38 |
18 |
|
50 |
6 |
|
43 |
13 |
|
| 3 |
36 |
4 |
|
22 |
18 |
|
36 |
4 |
|
25 |
15 |
|
| ER |
|
|
0.724 |
|
|
0.576 |
|
|
0.439 |
|
|
1.000 |
| 0 |
22 |
4 |
|
15 |
11 |
|
22 |
4 |
|
19 |
7 |
|
| 1 |
56 |
7 |
|
42 |
21 |
|
58 |
5 |
|
45 |
18 |
|
| PR |
|
|
0.266 |
|
|
1.000 |
|
|
0.244 |
|
|
0.898 |
| 0 |
19 |
5 |
|
15 |
9 |
|
20 |
4 |
|
18 |
6 |
|
| 1 to 3 |
59 |
6 |
|
42 |
23 |
|
60 |
5 |
|
46 |
19 |
|
| HER2 |
|
|
1.000 |
|
|
0.918 |
|
|
1.000 |
|
|
0.831 |
| 0 |
46 |
7 |
|
33 |
20 |
|
47 |
6 |
|
37 |
16 |
|
| 1 to 3 |
31 |
4 |
|
23 |
12 |
|
32 |
3 |
|
26 |
9 |
|
| Age |
|
|
0.758 |
|
|
1.000 |
|
|
0.723 |
|
|
0.453 |
| < 50 |
51 |
8 |
|
37 |
22 |
|
54 |
5 |
|
40 |
19 |
|
| ≥ 50 |
35 |
4 |
|
25 |
14 |
|
34 |
5 |
|
30 |
9 |
|
| LVIa |
|
|
1.000 |
|
|
0.746 |
|
|
0.716 |
|
|
0.564 |
| 0 |
26 |
3 |
|
17 |
12 |
|
27 |
2 |
|
19 |
10 |
|
| 1 to 2 |
58 |
7 |
|
42 |
23 |
|
58 |
7 |
|
48 |
17 |
|
| PNIb |
|
|
0.682 |
|
|
0.077 |
|
|
0.678 |
|
|
0.022a |
| 0 |
62 |
9 |
|
48 |
23 |
|
63 |
8 |
|
16 |
55 |
|
| 1 | 18 | 1 | 8 | 11 | 18 | 1 | 10 | 9 | ||||
aLymphatic vessel invasion.
bPerineural invasion.
cHazard score = TMEM16A score + PPFIA1 score – FADD score.
dP < 0.05.
ER, estrogen receptor; HER2, human epidermal growth factor; PR, progesterone receptor.